Search Results

Spectrum Dynamics Medical, a leading innovator in diagnostic imaging solutions, announced that its VERITON-CT 400, a new generation of digital SPECT/CT was successfully installed and patient scanning was started at Gustave Roussy, Grand Paris, France.

Sofinnova Partners and Gustave Roussy announced the launch of a strategic collaboration as part of Sofinnova Biovelocita, the first pan-European investment strategy dedicated to the creation and acceleration of biotech startups.

SOPHiA GENETICS, a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced the expansion of its relationship with Gustave Roussy, the leading cancer center in Europe.

Partnership will leverage Gustave Roussy’s tumor samples and Veracyte’s Biopharma Atlas multi-omic database and machine learning capabilities.

Gustave Roussy and THERYQ announce a strategic and structuring partnership to roll out and assess FLASH technology for radiotherapy.

LinKinVax, a clinical-stage biotechnology company focusing on innovative protein-based vaccines, and Gustave Roussy, the leading cancer centre in Europe ranked third Best Cancer Hospital in the world, announced the treatment at Gustave Roussy of the first patient in a Phase I/IIa clinical study with CD40HVac, a new therapeutic vaccine candidate for HPV-positive oropharyngeal cancer.

France’s Gustave Roussy Institute, Europe’s leading cancer center and ranked third in the world according to Newsweek Magazine, has chosen to partner with Synapse Medicine, a leader in clinical pharmacy and medication reconciliation.

OSE Immunotherapeutics joins key opinion leaders Dr Stephen Liu, associate professor and director of Thoracic Oncology at Georgetown University Lombardi Comprehensive Cancer Center and Prof Benjamin Besse, medical oncologist and director of clinical research at the Gustave Roussy Institute, to discuss the current unmet medical needs in lung cancer therapeutics and the development landscape of OSE Immunotherapeutics therapeutic cancer vaccine, Tedopi®.

MaaT Pharma informs on the completion of patient recruitment for the Phase 2a clinical trial1 sponsored by AP-HP2 and in collaboration with INRAE and Institut Gustave Roussy, evaluating MaaT013, the Company’s lead product candidate, in combination with immune checkpoint inhibitors, ipilimumab and nivolumab.

LinKinVax and Gustave Roussy announced a collaboration to conduct a first-in-human Phase I/IIa clinical trial with CD40HVac, a new therapeutic vaccine candidate against head and neck cancer associated with human papillomavirus (HPV).